Hemolytic Anemia

Plasmapheresis in autoimmune hemolytic anemia – pro

Autoimmune hemolytic anemia (AIHA) due to the presence of warm agglutinins is almost always due to IgG antibodies that react with protein antigens on the red blood cell (RBC) surface at body temperature. For this reason, they are called "warm agglutinins" even though they seldom directly agglutinate the RBCs. IV Gammaglobulin blocks this process. I some cases, AIHA can be characterised by a chronic course and an unsatisfactory control of haemolysis,

Read more
Procrit for anemia of Hepatitis C treatment – pro

Procrit is appropriate in the anemias due to erytrhopoietin underproduction or deficiency. In Hepatitis C it is usually both as well as due to chronic illness. Several studies have evaluated the use of recombinant human erythropoietin alfa (rHuEPO) (Procrit and Epogen) for the treatment of ribavirin/interferon-induced anemia in HCV-infected patients. In a letter to the editor of Hepatology, researchers in France reported the results of a study of

Read more
Autoimmune hemolytic anemia basics – pro

Lay Summary: I discuss some very basic facts about AIHA. Autoimmune hemolytic anemia (AIHA) due to the presence of warm agglutinins is almost always due to IgG antibodies that react with protein antigens on the red blood cell (RBC) surface at body temperature. For this reason, they are called "warm agglutinins" even though they seldom directly agglutinate the RBCs. IV Gammaglobulin blocks this process. I some cases, AIHA can be characterised by a

Read more
Aranesp intravenously – pro

Lay Sumamry: Aranesp intravenously works as well as by injection under the skin. Darebpoietin is FDA approved for sq administration unlike erytrhopoietin. However, there are situations in which IV adminsitration is more convenient for the patient, such as, for example, when there is on onging IV line for another reason. The two most common settings of this kind are the neonates and patients on dyalisis. The treatment of renal anaemia using erythropoiesis

Read more
Rituxan for Auto-Immune Hemolytic Anemia – pro

The evidence for use of rituximab in autoimmune hemolytic anemia has until reently been limited to case reports and small, uncontrolled clinical studies; however, there are many of them, and more recently larger trials, such as Barcellini et al have been performed and an evidence based recommendation(Crowder et al) appeared. Rituximab appeared to have efficacy in the treatment of AIHA, both idiopathic or associated with B-cell chronic lymphoproliferative

Read more

Fatal error: Call to undefined function fw_blog_pagination() in /home/content/43/9379243/html/wp-content/themes/wisdom/blog_category.php on line 39